NexGen Biomedical offers RNAi / PSR platform technology for sale

Jun 8 2010

NexGen Biomedical, Inc. announced today that it is offering its RNAi / PSR platform technology for sale.  "While technologies like siRNA are well suited for disease conditions involving expression of a single protein, the RNAi / PSR technology is better suited for conditions involving  expression of a broad spectrum of proteins such as happens with cell hyperproliferation, inflammation, and viral infections.  Combined with the pharmacokinetics, the technology is ideally suited to provide inexpensive topical and inhalable treatments for COPD, Asthma, Psoriasis, Rheumatoid Arthritis, Macular Degeneration, Herpes Lesions, Anti-aging Exfoliation, and Acne," NexGen's founder Mark Zamoyski explained.

"The second blockbuster advantage is that RNAi / PSR does not require complicated stabilization or delivery technologies.  The drug can readily be delivered only where needed by topical application or inhalation," Mr. Zamoyski added.

NexGen also announced it has formally retained the services of Richard Lepidi to oversee the sale of the technology.  "The commercialization of such a broad platform technology is beyond NexGen's resources," Mr. Lepidi explained.  "The 5 issued and 1 pending US patents cover almost a dozen therapeutic indications.  We therefore will seek an acquirer that can take full advantage of the therapeutic potential of the technology," said Mr. Lepidi.